Literature DB >> 15188517

Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord.

Yi-Ning Sun1, Jin-Yan Luo.   

Abstract

AIM: To investigate the mechanisms of tegaserod, a partial 5-HT4 agonist, in reducing visceral sensitivity by observing Fos, substance P (SP) and calcitonin gene-related peptide (CGRP) expression in the lumbarsacral spinal cord induced by colonic inflammation in rats.
METHODS: Twenty-four male rats with colonic inflammation induced by intraluminal instillation of trinitrobenzenesulfonic acid (TNBS) were divided into 3 groups. Treatment group 1: intra-gastric administration of tegaserod, 2 mg/kg.d; Treatment group 2: intra-gastric administration of tegaserod, 1 mg/kg.d; CONTROL GROUP: intra-gastric administration of saline, 2.0 mL/d. After 7 d of intra-gastric administration, lumbarsacral spinal cord was removed and processed for Fos, SP and CGRP immunohistochemistry.
RESULTS: In rats of the control group, the majority of Fos labeled neurons was localized in deeper laminae of the lumbarsacral spinal cord (L(5)-S(1)). SP and CGRP were primarily expressed in the superficial laminae of the spinal cord after TNBS injection. Intra-gastric administration of tegaserod (2 mg/kg.d) resulted in a significant decrease of Fos labeled neurons (22.0+/-7.7) and SP density (12.5+/-1.4) in the dorsal horn in the lumbarsacral spinal cord compared to those of the control group (62.2+/-18.9, 35.9+/-8.9, P<0.05). However, CGRP content in dorsal horn did not significantly reduce in rats of treatment group 1 (1.2+/-1.1) compared to that of the control group (2.8+/-2.4, P>0.05). Neither Fos expression nor SP or CGRP density in the dorsal horn significantly declined in rats of treatment group 2 compared to those of the control group (P>0.05).
CONCLUSION: Tegaserod can significantly reduce Fos labeled neurons in the lumbarsacral spinal cord induced by colonic inflammation. Tegaserod may reduce visceral sensitivity by inhibiting SP expression in the dorsal horn of spinal cord.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188517      PMCID: PMC4572280          DOI: 10.3748/wjg.v10.i12.1830

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

2.  Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain.

Authors:  N Friese; L Diop; E Chevalier; F Angel; P J Rivière; S G Dahl
Journal:  Regul Pept       Date:  1997-05-14

Review 3.  Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations.

Authors:  L Bueno; J Fioramonti; M Delvaux; J Frexinos
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

4.  Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.

Authors:  B Coffin; J-P Farmachidi; P Rueegg; A Bastie; D Bouhassira
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  Colonic inflammation induces fos expression in the thoracolumbar spinal cord increasing activity in the spinoparabrachial pathway.

Authors:  Richard J Traub; Anne Murphy
Journal:  Pain       Date:  2002-01       Impact factor: 6.961

Review 6.  Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence.

Authors:  Terence J Coderre; Joel Katz; Anthony L Vaccarino; Ronald Melzack
Journal:  Pain       Date:  1993-03       Impact factor: 6.961

Review 7.  Pharmacology of serotonin as related to anesthesia.

Authors:  L Gyermek
Journal:  J Clin Anesth       Date:  1996-08       Impact factor: 9.452

8.  Postsynaptic dorsal column neurons express NK1 receptors following colon inflammation.

Authors:  J Palecek; V Paleckova; W D Willis
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Authors:  J Novick; P Miner; R Krause; K Glebas; H Bliesath; G Ligozio; P Rüegg; M Lefkowitz
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171

10.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

Authors:  H Mertz; B Naliboff; J Munakata; N Niazi; E A Mayer
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

View more
  6 in total

Review 1.  Supraspinal Mechanisms of Intestinal Hypersensitivity.

Authors:  Olga A Lyubashina; Ivan B Sivachenko; Sergey S Panteleev
Journal:  Cell Mol Neurobiol       Date:  2020-10-08       Impact factor: 5.046

2.  Acupuncture relieves the visceral pain of diarrhea-predominant irritable bowel syndrome rats by regulating P2X4 expression.

Authors:  He-Yong Tang; Xi-Qiuyu Chen; Hao Wang; Hao-Ran Chu; Cai-Feng Zhu; Shun Huang; Meng-Ting Zhang; Guo-Ming Shen
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 3.  Serotonin pharmacology in the gastrointestinal tract: a review.

Authors:  D T Beattie; J A M Smith
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-09       Impact factor: 3.000

Review 4.  Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.

Authors:  Emily V Wechsler; Eric D Shah
Journal:  Drugs       Date:  2021-11-02       Impact factor: 9.546

5.  Understanding and targeting centrally mediated visceral pain in inflammatory bowel disease.

Authors:  Kristen E Farrell; Robert J Callister; Simon Keely
Journal:  Front Pharmacol       Date:  2014-03-05       Impact factor: 5.810

Review 6.  Tegaserod for the Treatment of Irritable Bowel Syndrome.

Authors:  Valentina Noemi Madia; Antonella Messore; Francesco Saccoliti; Valeria Tudino; Alessandro De Leo; Daniela De Vita; Martina Bortolami; Luigi Scipione; Ivano Pindinello; Roberta Costi; Roberto Di Santo
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.